Get the Stockscreener App
1.84
5.15%
-0.10
Pre-market:
1.90
0.06
+3.26%
Lexicon Pharmaceuticals Inc stock is currently priced at $1.84, with a 24-hour trading volume of 1.59M.
It has seen a -5.15% decreased in the last 24 hours and a +8.55% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.96 pivot point. If it approaches the $1.82 support level, significant changes may occur.
Previous Close:
$1.94
Open:
$1.94
24h Volume:
1.59M
Market Cap:
$665.15M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-2.7059
EPS:
-0.68
Net Cash Flow:
$-162.37M
1W Performance:
-2.65%
1M Performance:
+8.55%
6M Performance:
+73.58%
1Y Performance:
-37.20%
1D Range:
$1.835
$1.952
52W Range:
$0.92
$3.73
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
281-863-3000
Address
8800 Technology Forest Place, The Woodlands
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Short Interest Update - Defense World
Defense World
Here's Why Lexicon Pharmaceuticals Dropped as Much as 13.6% Today - Yahoo News UK
Yahoo News UK
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Passes Above 200 Day Moving Average of $1.77 - MarketBeat
MarketBeat
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Passes Above Two Hundred Day Moving Average of $1.77 - Defense World
Defense World
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
GlobeNewswire Inc.
Earnings call: Lexicon Pharmaceuticals Q1 2024 financial results and CEO retirement - Investing.com
Investing.com
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Lexicon Pharmaceuticals Inc (LXRX) Revenue 2024
LXRX reported a revenue (TTM) of $1.21 million for the quarter ending December 31, 2023, a +766.91% rise year-over-year.
Lexicon Pharmaceuticals Inc (LXRX) Net Income 2024
LXRX net income (TTM) was -$177.12 million for the quarter ending December 31, 2023, a -73.74% decrease year-over-year.
Lexicon Pharmaceuticals Inc (LXRX) Cash Flow 2024
LXRX recorded a free cash flow (TTM) of -$162.37 million for the quarter ending December 31, 2023, a -80.05% decrease year-over-year.
Lexicon Pharmaceuticals Inc (LXRX) Earnings per Share 2024
LXRX earnings per share (TTM) was -$0.80 for the quarter ending December 31, 2023, a -31.15% decline year-over-year.
About Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 clinical development for the treatment of diabetes; and LX9211 that is in Phase 1 clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
4.27%
2.59%
Cap:
|
Volume (24h):